Pet Pharm Biotech Co (ROCO:7762) LT-Debt-to-Total-Asset : 0.06 (As of Jun. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Pet Pharm Biotech Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Pet Pharm Biotech Co's long-term debt to total assests ratio for the quarter that ended in Jun. 2024 was 0.06.

Pet Pharm Biotech Co's long-term debt to total assets ratio increased from Jun. 2023 (0.00) to Jun. 2024 (0.06). It may suggest that Pet Pharm Biotech Co is progressively becoming more dependent on debt to grow their business.

Pet Pharm Biotech Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Pet Pharm Biotech Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pet Pharm Biotech Co LT-Debt-to-Total-Asset Chart

Pet Pharm Biotech Co Annual Data

Trend

Dec22

Dec23

LT-Debt-to-Total-Asset

0.20

0.09

Pet Pharm Biotech Co Semi-Annual Data
	Dec22	Jun23	Dec23	Jun24
LT-Debt-to-Total-Asset	0.20	-	0.09	0.06

Pet Pharm Biotech Co LT-Debt-to-Total-Asset Calculation

Pet Pharm Biotech Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	41.63	/	487.577
	=	0.09

Pet Pharm Biotech Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (Q: Jun. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jun. 2024 )	/	Total Assets (Q: Jun. 2024 )
	=	39.371	/	662.22
	=	0.06

Pet Pharm Biotech Co (ROCO:7762) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Pet Pharm Biotech Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Pet Pharm Biotech Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Pet Pharm Biotech Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pet Pharm Biotech Co Ltd (ROCO:7762) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

143, Hougang 1st Road, 1-2F., No. 141, Xinzhuang District, New Taipei City, TWN, 242051

Website

https://www.petpharmbio.com

Pet Pharm Biotech Co Ltd is a Pharmaceutical company. The company is engaged in manufacturing medicinal products and medicine drugs. The products offered by the company include FDG Fluodeoxyglucose Injection (18F-FDG), Naolixi Injection (18F-FBB), Sodium fluoride injection (18F-NaF), and others.

Pet Pharm Biotech Co Headlines

No Headlines